Pharmaceuticals
Novo Nordisk shares plunge 10% after Alzheimer’s drug trial fails to hit key target
The Novo Nordisk A/S headquarters in Bagsvaerd, Denmark, on Wednesday, Nov. 5, 2025. Nichlas Pollier | Bloomberg | Getty Images Shares of Novo Nordisk on Monday fell as much 11% after the Danish drug pharmaceutical company said a highly-anticipated trial for Alzheimer’s disease failed to meet its main goal. The trial tested whether semaglutide — the […]
Read More
Eli Lilly hits $1 trillion market value, a first for a health-care company
A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Eli Lilly reached a $1 trillion market capitalization on Friday, the first health-care company in the world to join the exclusive club dominated by tech firms. Eli Lilly briefly hit […]
Read More
Obesity-drugmaker Novo Nordisk helps drive Denmark’s fastest growth in years
Denmark’s economic growth accelerated in the third quarter, boosted by strong pharmaceutical exports, a key industry for the small Nordic country home to weight loss drugmaker Novo Nordisk. Denmark’s seasonally adjusted gross domestic product (GDP) grew by 2.3% in the third quarter, the largest quarter-on-quarter expansion since the fourth quarter of 2021, a preliminary reading […]
Read More
Novartis sees sales boost from key cancer drugs
FILE PHOTO: The logo of Swiss drugmaker Novartis is seen at the company’s new cell and gene therapy factory in Stein, Switzerland, November 28, 2019. Arnd Wiegmann | Reuters Swiss drugmaker Novartis on Thursday forecast sales growth of 5% to 6% per year to 2030, on a currency-adjusted basis, as higher forecast peak sales for […]
Read More
Novo Nordisk cuts direct-to-consumer prices for Wegovy, Ozempic to $349 a month
Boxes of Ozempic and Wegovy made by Novo Nordisk at a pharmacy in London on March 8, 2024. Hollie Adams | Reuters Novo Nordisk on Monday said it has cut the direct-to-consumer prices of its blockbuster weight loss drug Wegovy and diabetes counterpart Ozempic, adding to efforts by the company and the Trump administration to […]
Read More
Novo Nordisk’s leadership strategy tested as shareholders signal frustration ahead of vote on board revamp
Flags with the logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy are pictures while the company presents the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025. Mads Claus Rasmussen | Afp | Getty Images A leadership shakeup at what was once Europe’s […]
Read More
WeightWatchers to offer Novo Nordisk’s Wegovy pill after 2026 launch
Wegovy injection pens arranged in Waterbury, Vermont, US, on Monday, April 28, 2025. Shelby Knowles | Bloomberg | Getty Images WeightWatchers’ CEO said on Wednesday it plans to offer Novo Nordisk’s much-anticipated Wegovy in pill form if it is launched next year in the United States, deepening its tie-up with the Danish obesity drugmaker. The […]
Read More
Cheaper medicines, free beach trips: U.S. health plans tap prescriptions that feds say are illegal
Every step is a struggle for Bruce Zimmerman, whose health has been deteriorating since he was diagnosed with multiple sclerosis eight years ago. In 2019, Zimmerman said, his then-employer offered him an opportunity that sounded irresistible: He and his wife, Becky, could take all-expense-paid trips to the Cayman Islands and the Bahamas to retrieve the medication […]
Read More
Novo Nordisk walked away from a $10 billion biotech deal — and investors aren’t sure if that’s smart or scary
Novo Nordisk has a lot on its plate — and it may not all be healthy. The pharmaceutical giant pulled out of its bidding war against rival Pfizer for clinical-stage biotech Metsera when the U.S. juggernaut matched its latest offer. Metsera accepted Pfizer’s $10 billion deal — significantly more than what Pfizer had initially offered […]
Read More
Metsera accepts Pfizer’s $10 billion bid in ongoing M&A battle
Smith Collection | Archive Photos | Getty Images Obesity drug developer Metsera said on Friday that it had accepted Pfizer‘s $10 billion acquisition offer, in what could spell the end of a bidding war between the New York-based pharma giant and rival Novo Nordisk that erupted over the last week. Pfizer had appeared to have […]
Read More